Abstract
Cancer biomarkers may be used to identify the presence of cancer and also help determine its stage, subtype, and whether they will respond to therapy. In a very recent review, Brennan et al. emphasize that the successful identification and translation of informative biomarkers aids clinical decision-making. Furthermore, they state that proteomics plays a very significant role in cancer biomarker discovery and validation. Also, these authors emphasize that antibody-based proteomics provides for additional information on cancer disease states. Individual cancer therapy may be promoted by antibody-based proteomics. Petricoin et al. (2006) have indicated that the blood peptidome provides a higher dimension of information content for cancer biomarker discovery. The peptidome is a low-molecular-weight-range circulatory proteome. These authors indicate that this could be a rich source of cancer-specific diagnostic information. They further emphasize that the peptidome is a recording of the cellular and extracellular enzymatic events taking place at the cancer-tissue microenvironment level.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
